Page 5 - Dr Reddys

Dr Reddy's shares zoom post Nicotinell acquisition; brokerages unimpressed

On Thursday, shares of the Dr Reddy's Laboratories zoomed up to 2.7 per cent at Rs 6,235.90 a piece on the BSE. The stock rose after the company on Wednesday acquired OTC brand Nicotinell

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

USFDA issues Form 483 with four observations to Dr Reddy's API unit

Dr Reddy's Laboratories on Friday said the US health regulator has issued Form 483 with four observations after inspecting its Andhra Pradesh-based API manufacturing facility. The US Food & Drug Administration (USFDA) today completed a GMP inspection at the company's API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh, the Hyderabad-based drug major said in a regulatory filing. The inspection was conducted from May 30, 2024 to June 7, 2024, it added. "We have been issued a Form 483 with four observations, which we will address within the stipulated timeline," the drug firm said. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Stocks to watch on June 04: DRL, Biocon, Wipro, RVNL, M&M Fin Svcs

Stocks to watch on June 04: RVNL has secured an engineering, procurement and construction order worth Rs 440 crore from South Central Railway

Drug makers Dr Reddy's, Sun Pharma, Aurobindo recall products in US market

Drug makers Dr Reddy's Laboratories, Sun Pharma and Aurobindo Pharma are recalling products in the US market due to manufacturing issues, as per the latest Enforcement Report of the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories is recalling close to 20,000 cartons of a medication used to control blood phenylalanine levels in adults and children. Princeton (New Jersey) based Dr Reddy's Laboratories, Inc, is recalling Javygtor (sapropterin dihydrochloride) Powder for Oral Solution (100mg) due to it being a "Sub-potent Drug", USFDA stated. The company is also recalling another lot of sapropterin dihydrochloride for the same reason, it added. The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. The USFDA said Sun Pharma is recalling 11,016 vials of Amphotericin B Liposome for Injection, used to treat fungal ...

Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings

The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy's

Dr Reddy's, Pidilite, UB, HZL, Voltas among six stocks to watch today

United Breweries announced a more than five-fold increase in net profit to Rs 80.15 crore for the January-March period of 2023-24 compared to the same period last year

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises

Stock picks by Anand Rathi: DR Reddy shows a strong uptrend with higher highs and higher lows on a weekly scale

Dr Reddy's Laboratories launches generic anti-bacterial medication in US

Dr Reddy's Laboratories on Friday said it has launched a generic medication, used to treat a wide variety of bacterial infections, in the US market. The company has launched Doxycycline Capsules (40 mg) in the US market, the Hyderabad-based drug maker said in a statement. The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA). Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.

Nestle India, Dr Reddy's to form joint venture for nutraceutical brands

This collaboration aims to expand their complementary nutraceutical portfolios in areas like metabolic care, hospital nutrition, general wellness, women's health, and child nutrition

Nestle India, Dr Reddy's to form JV for nutraceutical brands in India

Nestle India and Dr Reddy's Laboratories Ltd on Thursday announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to consumers in India and other agreed territories. A joint press release from the companies said the partnership will bring together the well-known global range of nutritional health solutions as well as vitamins, minerals, herbals and supplements of Nestle Health Science (NHSc) with the strong and established commercial strengths of Dr Reddy's in India. The move will help JV partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women's health and child nutrition for consumers across India, it said. Select brands will be licensed by the respective companies to the JV company. The Nestl Group will licence brands such as Nature's Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resour

Stocks to watch: Maruti Suzuki, NHPC, Dr Reddy's, Biocon, REC, GOCL Corp

Stocks to watch on March 28: Adani Power has awarded a contract valued at Rs 4,000 crore to Bharat Heavy Electricals for the establishment of a thermal power plant in Chhattisgarh

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent

With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company

Dr Reddy's Lab Q3 results: Net profit rises 11% on strong US, EU sales

For the Indian business in Q3 FY24, the revenue stood at Rs 1,180 crore Y-o-Y with a growth of 5 per cent and a sequential decline of 1 per cent

Dr Reddy's Lab Q3 results: PAT up 11%, beats estimates on strong US sales

The Hyderabad-based drug major had reported a net profit of Rs 1,247 crore for the October-December quarter of the last fiscal

Dr Reddy's recalls 8,000 bottles of generic drug in US over packaging error

Dr Reddy's Laboratories is recalling over 8,000 bottles of a generic medication used to prevent rejection of a transplanted organ from the US market due to a packaging error, according to the US Food & Drug Administration. The Hyderabad-based drug major is recalling 8,280 bottles of Tacrolimus capsules from the US market for "presence of foreign tablets/capsules" in the affected lot. One 0.5 mg Tacrolimus capsule was found in a bottle of 1 mg Tacrolimus capsules, the USFDA stated in its latest Enforcement Report. The affected lot was produced at Dr Reddy's Bachupally-based plant near Hyderabad. New Jersey-based Dr Reddy's Laboratories, Inc has initiated the nationwide (US) Class II recall on December 15, 2023. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Dr Reddy'

Dr Reddy's becomes 1st Indian pharma firm on Dow Jones Sustainability index

Dr. Reddy's Laboratories Ltd on Thursday said it has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda. Dr. Reddy's has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023, a press release from the drug maker said. Alongside its debut in DJSI World, the company retains its place in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the eighth year in a row based on Dr. Reddy's performance in the Standard & Poor Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria. Separately, Dr. Reddy's has been awarded Gold Medal' status by EcoVadis, the global sustainability ratings agency, for its score of 70 out of 100 in its scorecard for 2023. G V Prasad, Co-Chairman & Managing Director, Dr. Reddy's, said: As a company with over two decades of ...

A dose of concern for DRL: Sinks 5% on USFDA 'imminent' warning

Sell-off in response to a brokerage report, raising concerns about a warning on DRL's FTO 3